Skip to main content

Natalizumab (Tysabri)

Natalizumab is a second-line treatment for multiple sclerosis.

It acts by binding to α4β1-integrin and blocks its interaction with VCAM-1. This results in inhibition of leukocyte migration into the central nervous system.

It is administered through intravenous infusion every month.

In 2016, it sold €347 million in Europe.

It has an immunogenicity rate of 6-9%.

Labs that test for drug level:

Innsbruck Medical University


Labs that test for ADA titre:

Karolinska Institutet

Innsbruck Medical University

San Luigi Gonzaga University Hospital